Clinical Trial

Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The aim of this proposed study is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) in children's interstitial lung diseases(chILD) with genetic causes. This study is a randomized controlled clinical trial.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2020-08-26; most recent amendment 2026-03-13.
Status change: Not Yet Recruiting → Recruiting 2025-02-18
Trial Details
NCT Number NCT04532346
Lead Sponsor Children's Hospital of Fudan University
Conditions Interstitial Lung Disease, Surfactant Dysfunction
Enrollment 60 participants
Start Date 2024-09-01
Primary Completion 2026-10 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-03-16